5 August 2021 - Britain's competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law by charging the country's public health service "unfairly high" prices for an epilepsy drug, after being asked to reassess a previous fine.

The drug makers made use of a loophole so that the capsules, called Epanutin before September 2012, were not subject to price regulation for branded drugs, the Competition and Markets Authority found in its provisional review disclosed on Thursday.

Read Reuters article